Bavarian Nordic Reports the US FDA’s BLA Acceptance of CHIKV VLP Vaccine to Prevent Chikungunya
Shots:
- The US FDA has accepted & granted priority review to the BLA of CHIKV VLP vaccine in patients (≥12yrs.) for prevention of chikungunya virus infection, with the decision anticipated on Feb 14, 2025
- Following the CHMP’s positive opinion in Feb 2024, the EMA is reviewing the MAA of the vaccine under accelerated assessment, seeking EC’s approval in H1’25
- CHIKV VLP, an adjuvanted VLP-based vaccine, is a single-dose vaccine intended for active immunization to prevent CHIKV infection. It will be manufactured as a pre-filled syringe, if approved
Ref: Bavarian Nordic | Image: Bavarian Nordic
Related News:- Bavarian Nordic’s CHIKV VLP Receives EMA’s Accelerated Assessment for Chikungunya
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
